Clinical Trial Update: A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating plerixafor/G-CSF as conditioning agents before TCR alpha/beta depleted HSCT in patients with Wiskott-Aldrich Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Failure
• Hematopoietic Stem Cell Transplantation
• Wiskott-aldrich Syndrome

Drugs mentioned

• G-CSF (granulocyte colony-stimulating factor)
• Plerixafor (Plerixafor)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation | Phase 2 | Status: UNKNOWN